20 November 2019
The Russian Ministry of Health approved the first generic immunomodulator pomalidomide for the treatment of orphan disease – multiple myeloma. Information on this is available on the website of the State register of registered drugs in Russia (SRRD). The first generic of the choleretic drug gimecromona was also approved.
Two fixed combinations of the antimicrobial drugs ornidazole + ciprofloxacin and the antihypertensive drugs amlodipine + valsartan were registered. In total, according to the SRRD data, in the first two weeks of November, 17 drugs were registered:
Orcepol VM (ornidazole + ciprofloxacin), Terbinafine (terbinafine), Pomalidomide-TL (pomalidomide), Abacavir (abacavir), Furacilin-Alium (nitrofuran), Yopamiskan (yopamidol), Emopag (ethylmethylhydroxypyridine acetylglutaminate), Valz Combi (amlodipine + valsartan), Desloratadine Velfarm, Gimekromon-SZ (Gimekromon), Rimantadine” (rimantadine), Hydrochlorothiazide + Losartan (hydrochlorothiazide + losartan), Cetirizine (cetirizine), Neuropol (citicoline), Naphthyzine (naphazoline), Heli-stop (bismuth tripotassium dicitrate), Rosuvastatin (rosuvastatin).
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia has expanded the mandatory health insurance program for 2024-2026
29 March 2024
Russian scientists have developed new TB vaccines for both injection and nasal administration.
29 March 2024
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024